Long-term oclacitinib administration for feline allergic pruritus: a retrospective study of 14 client-owned cats

Table S1: Oclacitinib treatment details for each patient.

Case	*Initial oclacitinib dosage (dosage reduction date)*	*Maintenance oclacitinib dosage*	*Oclacitinib duration (mo)*	*Concomitant treatments while on oclacitinib (when occurred)*	*Non-dermatological disorders while on oclacitinib treatment (when occurred)*
1	1.1 mg/kg/12h	No changes	20	ASIT, selamectin/sarolaner spot-on (frequency unknown in the long-term)	None
2	1.6 mg/kg/12h (3 y AB)	1.1 mg/kg/24h	42	Pradofloxacin (beginning), methylprednisolone acetate (beginning), ICZ (2 y AB), selamectin/sarolaner spot-on (frequency unknown in the long-term)	None
3	0.6 mg/kg/12h (15 d AB)	0.6 mg/kg/24h	68	Benazepril URSP (5 y AB), selamectin spot-on (frequency unknown in the long-term)	None
4	0.8 mg/kg/12h	No changes	27	Methylprednisolone (beginning), ICZ (7 mo AB), methylprednisolone URSP (17 mo AB), marbofloxacin URSP (17 mo AB), azithromycin URSP (19 m AB) selamectin/sarolaner spot-on (frequency unknown in the long-term)	Rhinitis (17 mo AB)

5	1.1 mg/kg/12h (15 d AB)	0.6 mg/kg/24h	7	Meloxicam & maropitant URSP (7m AB), selamectin/sarolaner spot-on (frequency unknown in the long-term)	Isolated idiopathic cystitis (7 mo AB), occasional vomiting episodes
6	1.1 mg/kg/12h (15d AB)	1.1 mg/kg/24-48h	23	ASIT, selamectin/sarolaner spot-on (frequency unknown in the long term)	None
7	0.9 mg/kg/12h (15 d AB)	0.9 mg/kg/24-72h	23	ASIT, bet/gen ointment (occasionally), lotilaner (frequency unknown in the long-term)	None
8	0.9 mg/kg/12h (15 d AB)	0.9 mg/kg/24h	15	Spiramycin-metronidazole URSP, probiotics (Fortiflora® PRO PLAN®) and fenbendazole (10m AB), selamectin/sarolaner spot-on (frequency unknown in the long-term)	Colitis (10m AB)
9	1.1 mg/kg/12h	No changes	14	Clorhexidine (beginning), selamectin/sarolaner spot-on (frequency unknown in long-term)	Lethargy (1st month)
10	1.2 mg/kg/12h	No changes	11	Prednisolone (beginning), fipronil/(s)-methoprene/eprinomectin/praziquantel spot-on (frequency unknown in long-term)	None
11	1.3 mg/kg/12h (1 mo AB)	1.3 mg/kg/24 h	16	Clorhexidine (beginning) and gabapentin (1 mo AB), selamectin/sarolaner spot-on (frequency unknown in the long-term)	None
12	1.2 mg/kg BID	No changes	13	Prednisolone (beginning)	None

13	1.3 mg/kg/12h	No changes	13	Probiotics (Fortiflora® PRO PLAN®)(chronic tt), selamectin/sarolaner spot-on (frequency unknown in the long-term)	None
14	1.2 mg/kg/12h	No changes	12	Frunevetmab & inhaled fluticasone URSP, selamectin/sarolaner spot-on (frequency unknown in the long-term)	None

Abbreviations: AB: after beginning; ASIT: allergen-specific immunotherapy; bet/gen: betamethasone/gentamicin; d: days; GCC: glucocorticoids; ICZ: itraconazole; URSP: unrelated to skin problems;

Table S2: Blood test major abnormalities during oclacitinib treatment for each patient.

Case	*CBC main abnormalities (reference interval varied among laboratories) (blood test performed period)*	*BCH main abnormalities (reference interval varied among laboratories) (blood test performed period)*
1	No major abnormalities	ALT 136 UI/L (31-92) (24-36 mo). No more tests performed afterwards
2	Lymph 876 cells/µL (1500-7000) (12-18 mo), 708 cels/µL (850-5850) (18-24 mo). Normalized afterwards (36-48 mo) Eos 2367 cels/µL (90-2180) (18-24 mo). Normalized afterwards (36-48 mo) Mono 56.7/µL (100-700) (24-36 mo). Normalized afterwards (36-48 mo)	Gluc 156 mg/dL (57-131) (0-6 mo) Normalized afterwards (12-18 mo; 18-24 mo, 24-36 mo) Crea (high from the beginning, no changes over treatment) 1.8 mg/dL (T0), 1.67 mg/dL (0-6 mo), 1.88 mg/dL (12-18 mo), 2.12 mg/dL (<1.60) (24-36 mo), 1.8 mg/dL (<2.3) (36-48 mo). SDMA within the reference interval. No more tests performed afterwards Urea 77 mg/dL (30-60) (24-36 mo). Normalized afterwards (36-48 mo)
3	Neutr 2240 cells/µL (0-6 mo), 2431 cells/µL (12-18 mo) (2620-15170). Normalized afterwards (24-36 mo; 36-48 mo; 60-72 mo) Plt 119000/µL (12-18 mo), 144000/µL (24-36 mo) (155000-641000). Normalized afterwards (36-48 mo; 60-72 mo)	Gluc 175 mg/dL (12-18 mo), 191 mg/dL (60-72 mo) (59-160). No further tests ALT 131 UI/L (31-92) (24-36 mo). Normalized afterwards (36-48 mo; 60-72 mo) Crea 1.6 mg/dL (0-6 mo), 1.7 mg/dL (6-12 mo) , 2.0 mg/dL (12-18 mo) ,1.6 mg/dL (24-36 mo) , 1.8 mg/dL (36-48 mo), 1.8 mg/dL (60-72 mo) (0.9-2.3). Urea within reference interval. No further tests SDMA 23 µg/dl (0-14) (6-12 mo). Normalized afterwards (12-18 mo; 24-36 mo; 36-48 mo; 60-72 mo)

4	Leuko 22.41 10^3/µL (3.9-19) (0-6 mo). Normalized afterwards (6-12 mo) Mono 1569 cells/µL (40-530) (0-6 mo). Normalized afterwards (6-12 mo) Eos 2241 cells/µL (90-2180) (0-6 mo). Normalized afterwards (6-12 mo) Baso 1345 cells/µL (0-100) (0-6 mo). Normalized afterwards (6-12 mo)	ALT 112 UI/L (31-92) (T0). Normalized afterwards (0-6 mo; 6-12 mo)
5	Lymph 0.79 K/µL (0.92-6.88) (T0). Normalized afterwards (6-12 mo) Neutr 13.54 K/µL (2.3-10.29) (6-12 mo). No further tests	No major abnormalities
6	Ht 36.7% (37-54) (T0). Normalized afterwards (0-6 mo; 6-12 mo) Hb 11.8 g/dL (13.3-19) (T0). Normalized afterwards (0-6 mo; 6-12 mo) Leuko 6x10^3/µL (0-6 mo), 4.4 x10^3/µL (18-24 mo) (6.4-15.9). No further tests Lymph 0.5x10^3/µL (1.5-7) (18-24 mo). No further tests	ALT 68 UI/L (6-50) (T0), 67 UI/L (0-41) (18-24 mo). No more tests performed afterwards Gluc 213 mg/dL (0-6 mo), 169 mg/dL (6-12 mo) (60-120). No further tests Chol 282 mg/dL (0-200) (18-24 mo). No further tests

	Plt 83.000/µL (0-6 mo), 132.000/µL (6-12 mo) (186.000-550.000). Normalized afterwards (18-24 mo)	
7	Plt 274.000/µL (300.000-800.000) (18-24 mo). No further tests	ALT 56 UI/L (6-50) (6-12 mo). Normalized afterwards (18-24 mo)
8	Neutr 10.74 K/µL (2.3-10.29) (6-12 mo). Normalized afterwards (12-18 mo)	No major abnormalities
9	No major abnormalities	Chol 175 mg/dL (70-150) (T0), 137 mg/dL (61-135) (12-18 mo). No further tests Crea 1.68 mg/dL (0.9-1.6) (12-18 mo). Urea within the reference interval. No further tests
10	Eos 1459.9 cells/µL (100-1200) (6-12 mo). No further tests	Chol 242 mg/dL (61-135) (6-12 mo). No further tests
11	Ht 24.6% (26-47) (T0). Normalized afterwards (12-18 mo) Hb 8.3 g/dL (8.5-15.3) (T0). Normalized afterwards (12-18 mo) Plt 68 10^9/L (100-518) (T0). Normalized afterwards (12-18 mo) Lymph 595 cells/µL (1200-10400) (12-18 mo). No further tests	Gluc 222 mg/dL (53-150) (T0). No further tests Chol 181 mg/dL (61-135) (12-18 mo). No further tests

12	Eos 1373 cells/µL (T0), 1386 cells/µL (6-12 mo) (100-1200). No further tests Leuko 3480 cells/µL (3800-17200) (12-18 mo). No further tests Lymph 1078 cels/µL (1200-10400) (12-18 mo). No further tests	Gluc 168 mg/dL (60-120) (6-12 mo). No further tests
13	Mono 63.8 cels/µL (100-700) (T0). Normalized afterwards (0-6 mo; 12-18 mo)	Crea 1.64 mg/dL (0.9-1.6) (0-6 mo). Normalized afterwards (12-18 mo) ALT 61 U/L (T0), 62 U/L (0-6 mo) (18-54). Normalized afterwards (12-18 mo) Chol 167 mg/dL (T0), 236 mg/dL (0-6 mo) (61-135). Normalized afterwards (12-18 mo)
14	Eos 1502.4 cells/µL (100-1200) (6-12 mo). No further tests	Chol 205 mg/dL (T0), 138 mg/dL (0-6 mo), 143 mg/dL (6-12 mo) (61-135). No further tests

Abbreviations: ALT: alanine aminotransferase; Baso: basophils; BCH: biochemistry; CBC: complete blood count; Chol: cholesterol; Crea: creatinine; Eos: eosinophils; Gluc: glucose; Hb: haemoglobin; Ht: haematocrit; Leuko: leukocytes; Lymph: lymphocytes; Mono: monocytes; Neutr: neutrophils; Plt: platelets; PT: total proteins; SDMA: symmetric dimethylarginine.

Figures:



Figure S1: High ALT values in 6 cats and changes over time.



Figure S2: Hypercholesterolaemia in 6 cats and changes over time.



Figure S3: Hyperglycaemia in 5 cats and their changes during subsequent study periods.



Figure S4: High creatinine values in 4 cats and their changes during subsequent study periods.